| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ... New England journal of medicine 369 (18), 1691-1703, 2013 | 6702 | 2013 |
| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses S Jones, X Zhang, DW Parsons, JCH Lin, RJ Leary, P Angenendt, ... science 321 (5897), 1801-1806, 2008 | 4641 | 2008 |
| Pancreatic cancer M Hidalgo New England journal of medicine 362 (17), 1605-1617, 2010 | 3512 | 2010 |
| Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ... New England Journal of Medicine 373 (8), 726-736, 2015 | 1878 | 2015 |
| Patient-derived xenograft models: an emerging platform for translational cancer research M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ... Cancer discovery 4 (9), 998-1013, 2014 | 1665 | 2014 |
| A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development A Jimeno, G Feldmann, A Suárez-Gauthier, Z Rasheed, A Solomon, ... Molecular cancer therapeutics 8 (2), 310-314, 2009 | 1561* | 2009 |
| Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab S Khambata-Ford, CR Garrett, NJ Meropol, M Basik, CT Harbison, S Wu, ... Journal of clinical oncology 25 (22), 3230-3237, 2007 | 1399 | 2007 |
| Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies M Hidalgo, LL Siu, J Nemunaitis, J Rizzo, LA Hammond, C Takimoto, ... Journal of clinical oncology 19 (13), 3267-3279, 2001 | 1258 | 2001 |
| Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial DD Von Hoff, RK Ramanathan, MJ Borad, DA Laheru, LS Smith, TE Wood, ... Journal of Clinical Oncology 29 (34), 4548-4554, 2011 | 1232 | 2011 |
| Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma MB Atkins, M Hidalgo, WM Stadler, TF Logan, JP Dutcher, GR Hudes, ... Journal of clinical oncology 22 (5), 909-918, 2004 | 1188 | 2004 |
| DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer CA Iacobuzio-Donahue, B Fu, S Yachida, M Luo, H Abe, CM Henderson, ... Journal of clinical oncology 27 (11), 1806-1813, 2009 | 1175 | 2009 |
| Development of matrix metalloproteinase inhibitors in cancer therapy M Hidalgo, SG Eckhardt Journal of the National Cancer Institute 93 (3), 178-193, 2001 | 1099 | 2001 |
| Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of … D Soulieres, NN Senzer, EE Vokes, M Hidalgo, SS Agarwala, LL Siu Journal of clinical oncology 22 (1), 77-85, 2004 | 996 | 2004 |
| Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K Ballman, J Boni, ... Journal of Clinical Oncology 23 (23), 5294-5304, 2005 | 839 | 2005 |
| The rapamycin-sensitive signal transduction pathway as a target for cancer therapy M Hidalgo, EK Rowinsky Oncogene 19 (56), 6680-6686, 2000 | 783 | 2000 |
| Developing inhibitors of the epidermal growth factor receptor for cancer treatment V Grunwald, M Hidalgo Journal of the National Cancer Institute 95 (12), 851-867, 2003 | 662 | 2003 |
| Interrogating open issues in cancer precision medicine with patient-derived xenografts AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ... Nature Reviews Cancer 17 (4), 254-268, 2017 | 656 | 2017 |
| Pancreatic cancer: from state-of-the-art treatments to promising novel therapies I Garrido-Laguna, M Hidalgo Nature reviews Clinical oncology 12 (6), 319-334, 2015 | 631 | 2015 |
| Addressing the challenges of pancreatic cancer: future directions for improving outcomes M Hidalgo, S Cascinu, J Kleeff, R Labianca, JM Löhr, J Neoptolemos, ... Pancreatology 15 (1), 8-18, 2015 | 598 | 2015 |
| Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma ZA Rasheed, J Yang, Q Wang, J Kowalski, I Freed, C Murter, SM Hong, ... Journal of the National Cancer Institute 102 (5), 340-351, 2010 | 530 | 2010 |
